Transcriptional control of human diploid fibroblast collagen synthesis by γ-interferon

doi:10.1016/0006-291X(84)90422-4

Biochemical and Biophysical Research Communications

Volume 123, Issue 1, 30 August 1984, Pages 365-372

https://doi.org/10.1016/0006-291X(84)90422-4 Get rights and content

Abstract

Recombinant γ-interferon (rec γ-IFN) caused potent inhibition of collagen synthesis by cultured confluent human diploid fibroblasts in a dose-dependent manner. Gel electrophoresis of the newly synthesized proteins from the culture media of rec γ-IFN-treated fibroblasts demonstrated a selective depression of procollagen without a significant change in non-collagenous proteins. Dot blot hybridization to a Type I procollagen cDNA probe showed that the inhibition of collagen production was accompanied by a decrease in the levels of collagen mRNA. These results indicate that rec γ-IFN is capable of exerting transcriptional modulation of collagen biosynthesis and suggest that it may play an important role in regulation of normal and pathologic fibrogenesis.

References (15)

S.R. Pinnell
J. Invest. Dermatol
(1982)
K. Juva et al.
Anal. Biochem
(1966)
W. Burnett et al.
Biochem. Biophys. Res. Commun
(1979)
J.C. Myers et al.
J. Biol. Chem
(1983)
E.C. LeRoy
J. Clin. Invest
(1974)
R.L. Johnson et al.
J. Clin. Invest
(1976)
S.M. Wahl et al.
J. Immunol
(1978)

There are more references available in the full text version of this article.

Cited by (110)

Expression of galectin-9 by IFN-γ stimulated human nasal polyp fibroblasts through MAPK, PI3K, and JAK/STAT signaling pathways
2011, Biochemical and Biophysical Research Communications
Citation Excerpt :
IFN-γ exhibits diverse effects on cells of the immune system, serving as an important regulator of lymphocyte and macrophage functions [25,26]. IFN-γ also has anti-proliferative effects on many cell types, including fibroblasts [26–28]. Many genes, including those for various chemokines, are transcriptionally activated in IFN-γ treated cells.
Galectin-9 exhibited potent and selective eosinophil chemoattractant activity and attracted eosinophils in vitro and in vivo. Nasal polyposis is a chronic inflammatory disease of the upper airway characterized by the marked presence of inflammatory cells, particularly eosinophils. Thus, galectin-9 may be implicated in the pathogenesis of nasal polyposis. The study was designed to investigate whether interferon-gamma (IFN-γ) can induce the augmentation of galectin-9 expression and induce the expression of galectin-9 in nasal polyps. We examined the correlation between galectin-9 expression and eosinophil infiltration in nasal polyps. In addition, we identified the signaling pathways involved in the elevation of galectin-9 expression in response to IFN-γ. Our data demonstrate that the involvement of mitogen-activated protein kinases (MAPKs), phosphatidylinositol 3 phosphate kinase (PI3K), and Janus kinase/signal transducer and activator of transcription (JAK/STAT) may play important roles in the selective recruitment of eosinophils in nasal polyp tissues through the production of galectin-9. These findings suggest that galectin-9 expression is associated with eosinophil infiltration in polyps of patients with nasal polyposis.
Major histocompatibility class II transactivator (CIITA) mediates repression of collagen (COL1A2) transcription by interferon γ (IFN-γ)
2004, Journal of Biological Chemistry
Interferon γ (IFN-γ) plays an important role during inflammation by repressing collagen and activating major histocompatibility class II (MHC-II) expression. Activation of MHC-II by IFN-γ requires regulatory factor for X-box 5 (RFX5) complex as well as class II transactivator (CIITA). We have shown that the RFX family binds to the COL1A2 transcription start site (Sengupta, P. K., Fargo, J., and Smith, B. D. (2002) J. Biol. Chem. 277, 24926–24937), and the RFX5 complex represses COL1A2 gene expression during IFN-γ response (Xu, Y., Wang, L., Buttice, G., Sengupta, P. K., and Smith, B. D. (2003) J. Biol. Chem. 278, 49134–49144). In this report, we demonstrate that CIITA is a key mediator of COL1A2 repression by IFN-γ. IFN-γ up-regulates the expression of CIITA in a time-dependent manner in lung fibroblasts and promotes CIITA protein occupancy on COL1A2 transcription start site in vivo as judged by chromatin immunoprecipitation (ChIP) assays. There are coordinate decreases in the occupancy of RNA polymerase II on the collagen transcription start site with increasing CIITA occupancy during IFN-γ treatment. In addition, we are able to specifically knockdown the IFN-γ-stimulated expression of CIITA utilizing short hairpin interference RNA (shRNA) against CIITA. This leads to the alleviation of COL1A2 repression and MHC-II activation by IFN-γ. RFX5 recruits CIITA to the collagen site as evidenced by DNA affinity chromatography. The presence of RFX5 complex proteins enhances the collagen repression by CIITA reaching levels occurring during IFN-γ treatment. Co-expression of CIITA with deletion mutations and collagen promoter constructs demonstrates that CIITA represses collagen promoter mainly through its N-terminal region including the acidic domain and the proline/serine/threonine domain. Our data suggest that CIITA is a crucial member of a repressor complex responsible for mediating COL1A2 transcription repression by IFN-γ.
Two Distinct Mechanisms Underlying γδ T Cell-Mediated Regulation of Collagen Type I in Lung Fibroblasts
2022, Cells
Joel Rosenbloom and the revolution in biomedical research
2022, Connective Tissue Research
Normal and keloid fibroblasts are differentially influenced by IFN-γ and triamcinolone as well as by their combination
2019, Wound Repair and Regeneration
In situ cytokine expression and morphometric evaluation of total collagen and collagens Type I and Type III in Keloid scars
2017, Mediators of Inflammation

View all citing articles on Scopus

View full text

Transcriptional control of human diploid fibroblast collagen synthesis by γ-interferon

Abstract

J. Invest. Dermatol

Anal. Biochem

Biochem. Biophys. Res. Commun

J. Biol. Chem

J. Clin. Invest

J. Clin. Invest

J. Immunol